Lilly follows Biogen-Eisai in securing US FDA approval for Alzheimer's drug

(Reuters) - Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the progression of Alzheimer's disease.

Kisunla is now the second drug to get a traditional approval from the U.S. regulator for the brain-wasting disease after Biogen and Japan-based Eisai's Leqembi, marking a major milestone in a field that has witnessed multiple failures.

The following is a list of companies with approved therapies in the U.S. market and those currently developing treatments that aim to modify the memory-robbing disease:

Company Drug or Stage of Mechanism

Therapy development &

indication

Eli Lilly

and Co Kisunla Secured U.S. FDA's Designed to

target and

standard approval remove toxic

for protein plaque

early Alzheimer’s in the brain

known as

beta-amyloid to

slow down

cognitive

decline

The An

Eisai Co Leqembi first Alzheimer’s antibody

Ltd & treatment to designed to

Biogen Inc win remove sticky

beta-amyloid

standard approval deposits from

from the U.S. FDA the brain

BioVie NE3107 An oral small

Late-stage trial molecule that

for aims to inhibit

mild-to-moderate neuroinflammati

Alzheimer’s on and insulin

resistance

AB Science masitinib An oral

SA Late-stage study tyrosine kinase

for inhibitor that

mild-to-moderate targets immune

Alzheimer’s cells

responsible for

neuroinflammati

on

Annovis buntanetap An orally

Bio Mid-to-late-stage administered

trial for moderate small molecule

Alzheimer's inhibitor of

several

neurotoxic

proteins

Cognition CT1812 Oral drug

Therapeuti Mid-stage trial designed to

cs for bind to a

mild-to-moderate specific

Alzheimer’s receptor in

brain cells,

which mediates

beta-amyloid

attachment

Coya COYA 301 Designed to

Therapeuti Mid-stage trial inhibit

cs for molecules

mild-to-moderate responsible for

Alzheimer’s neuroinflammati

on and improve

cognitive

function

Actinogen xanamem Blocks the

Medical Mid-stage trial production of

Limited for the stress

mild-to-moderate hormone

Alzheimer's cortisol,

associated with

cognitive

impairment, in

brain cells

AC Immune ACI-24.060 An

SA Early-to-mid-stage antibody-based

trial for immunotherapy

Alzheimer’s vaccine

designed to

target

beta-amyloid

plaque

Biogen BIIB080 An antisense

Mid-stage trial oligonucleotide

for early-stage therapy

Alzheimer’s directed

against "tau"

proteins

Longeveron lomecel-B A cell therapy

Mid-stage trial designed to

for mild stimulate

Alzheimer’s neuroregenerati

on and prevent

the progression

of the disease

(Reporting by Pratik Jain and Mariam Sunny in Bengaluru; Editing by Maju Samuel and Pooja Desai)